Novel oral anticoagulants and anti-arrhythmic agents will drive atrial fibrillation drug market to increase more than eight-fold to $6.8 billion

The launch and uptake of novel oral anticoagulants and anti-arrhythmic agents - specifically, drugs from Boehringer Ingelheim, Bayer/Johnson & Johnson, Bristol-Myers Squibb/Pfizer and Sanofi-Aventis - will drive the atrial fibrillation drug market to increase more than eight-fold, from $843 million in 2009 to $6.8 billion in 2019, according to a new report from Decision Resources.

The Pharmacor 2010 findings, from the topic titled Atrial Fibrillation, reveal that the sales of novel oral anticoagulants will be led by Boehringer Ingelheim's Pradaxa (dabigatran etexilate), Bayer/Johnson & Johnson's Xarelto (rivaroxaban) and Bristol-Myers Squibb/Pfizer's apixaban. In 2019, novel oral anticoagulants will capture nearly three-quarters of the atrial fibrillation drug market in the USA, France, Germany, Italy, Spain, the UK and Japan.

Sanofi-Aventis' Multaq will also expand market